Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Turing’s Martin Shkreli Says He Should Have Increased the Price of Daraprim Higher than 5,000%

NEW YORK – Turing Pharmaceuticals’ Martin Shkreli, once dubbed the most hated man in America, might not have a difficult time holding onto that title after telling a healthcare panel he should have raised the price of Daraprim even higher than the 5,000 percent increase he did. “I think I could have raised it higher […]

Read More »

INSYS Responds to Allegations It Falsified Reports to Sell More of its Cancer Pain Treatment

PHOENIX – After its stock dropped nearly 20 percent, Insys Therapeutics defended its practices from allegations it falsified data in order to sell more of its painkiller, the fentanyl-based Subsys. The Arizona-based company said it is committed to patient safety and has complied with all law, including those related to adverse event reporting.   In […]

Read More »

Researchers Find Additional Benefits of Novartis AG’s Heart Failure Drug Entresto

Researchers at Brigham and Women’s Hospital have discovered even more promising data around a Novartis drug for heart failure, saying that the drug increased life expectancy by nearly two years. The research, published in the Dec. 3 issue of the New England Journal of Medicine, showed that patients that had reduced ejection fraction form — […]

Read More »

Alexion’s $550,000 bone drug too expensive for Britain

A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more than $550,000 a year for each patient has been deemed too expensive by Britain’s health cost watchdog NICE. The case highlights the sky-high price of some medicines for treating rare diseases and the dilemma this poses for cash-strapped […]

Read More »

Gilead put profit ahead of hepatitis C patients: U.S. Senate report

U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines. In the latest salvo against high U.S. prices for important medicines, the 18-month […]

Read More »

Where Gilead May Be a Decade from Now

FOSTER CITY, Calif. – Pharmaceutical prognosticators predict Gilead Sciences, Inc. (GILD) will remain a leader in providing therapies for hepatitis and HIV over the next decade, but also speculate the company will break ground in new treatment areas for oncology, respiratory and rheumatoid arthritis.   Contributors to The Motley Fool, an online investment news site, […]

Read More »

FDA approves new Bristol-Myers treatment for multiple myeloma

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp’s Revlimid and common anti-inflammatory drug […]

Read More »

Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Focused On GPCR Targets Across Multiple Therapeutic Areas

LONDON and BOSTON, November 30, 2015 /PRNewswire/ — Heptares Therapeutics (“Heptares”), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines […]

Read More »

Pfizer Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at […]

Read More »

FDA declines expanded approval for Bristol-Myers’ Opdivo drug

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer. Bristol-Myers said it received a so-called complete response letter from the health regulator, which indicated the need for additional data in the BRAF mutated patient […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom